Comparison of human liver S9, hepatocyte spheroids, and other in vitro systems for predicting peptide drug metabolism revealed important differences relevant to peptide therapeutic development.
Model choice mattersDifferent liver models gave different peptide metabolism predictions — choosing the right model is crucial for accurate peptide drug development
What the researchers found
Comparison of human liver S9, hepatocyte spheroids, and other in vitro systems revealed model-dependent differences in peptide metabolism prediction, informing best practices for peptide drug development.
Why it matters
Better liver metabolism prediction for peptides means more accurate dosing, fewer clinical failures, and faster drug development for the growing class of peptide therapeutics.
The numbers in context
4 peptides (cyclosporine, leuprorelin, desmopressin, cetrorelix); S9 most metabolites for 2; CYP-dependent metabolism found; hydrolytic similar across systems
How the study worked
In vitro metabolism study comparing multiple hepatic models for peptide degradation. Human liver S9 fractions and hepatocyte spheroids evaluated.
Who was studied
Human liver S9 fraction, cryopreserved hepatocytes, and Upcyte hepatocytes
What this study cannot tell us
In vitro models may not fully replicate in vivo liver metabolism. Limited number of peptide compounds tested. Inter-individual variability in human liver not fully captured.
How to read the evidence
Moderate evidence: systematic comparison of established in vitro liver models.
When this study was published
Published 2021.
The bigger picture
As peptide therapeutics proliferate, understanding their hepatic metabolism becomes increasingly important. Selecting the right in vitro model early in development can prevent costly clinical failures.
Questions still open
- Which liver model most accurately predicts peptide drug half-life in humans?
- Can in vitro metabolism data reliably predict peptide dosing intervals?
- Do modified peptides (PEGylated, lipidated) follow the same metabolic patterns?
Common questions
Why does liver metabolism matter for peptide drugs?
Why test different liver models?
Read the original research
Hepatic in vitro metabolism of peptides; Comparison of human liver S9, hepatocytes and Upcyte hepatocytes with cyclosporine A, leuprorelin, desmopressin and cetrorelix as model compounds.
Journal of pharmaceutical and biomedical analysis, 196, 113921
Citation
Jyrkäs, Juha; Tolonen, Ari. (2021). Hepatic in vitro metabolism of peptides; Comparison of human liver S9, hepatocytes and Upcyte hepatocytes with cyclosporine A, leuprorelin, desmopressin and cetrorelix as model compounds.. Journal of pharmaceutical and biomedical analysis, 196, 113921. https://doi.org/10.1016/j.jpba.2021.113921